Table 2.

VTE risk in patients with breast cancer by chemotherapy and genetic susceptibility

HR (95% CI)
N all/VTE casesModel 1Model 2Model 3Model 4
Chemotherapy
 No2,613/144REFREFREFREF
 Yes1,648/1321.80 (1.40–2.31)1.81 (1.41–2.33)1.83 (1.32–2.54)1.98 (1.40–2.80)
PRS (percentiles)
 <95%4,048/252REFREFREFREF
 ≥95%213/241.91 (1.25–2.90)1.88 (1.23–2.87)1.84 (1.20–2.82)1.90 (1.24–2.91)
Chemotherapy/PRS (percentiles)
 No chemo/PRS < 95%2,474/130REFREFREFREF
 Chemo/PRS < 95%1,574/1221.83 (1.41–2.36)1.81 (1.40–2.34)1.85 (1.32–2.59)1.98 (1.39–2.82)
 No chemo/PRS ≥ 95%139/141.97 (1.14–3.42)1.91 (1.09–3.34)1.88 (1.07–3.30)1.87 (1.06–3.28)
 Chemo/PRS ≥ 95%74/103.71 (1.93–7.14)3.68 (1.90–7.10)3.58 (1.79–7.16)3.84 (1.91–7.71)
  • Model 1: Model adjusted for age at diagnosis.

  • Model 2: Model 1 plus patient characteristics (menopausal status, VTE history, comorbidities, body mass index, smoking, physical activity, oral contraceptive use, and hormone replacement therapy).

  • Model 3: Model 2 plus tumor characteristics (tumor size, histological grade, number of affected lymph nodes).

  • Model 4: Model 3 plus treatment characteristics (endocrine therapy, radiotherapy, and surgery).